Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study

Ansell, 2008, American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines (8th Edition), Chest, 133, 160S, 10.1378/chest.08-0670 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 2010, Study Investigators. Rivaroxaban‐once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study, Am Heart J, 159, 340.e1 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 You, 2012, American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines, Chest, 141, e531S, 10.1378/chest.11-2304 Camm, 2012, 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association, Eur Heart J, 33, 2719, 10.1093/eurheartj/ehs253 Danish Health and Medicines Authority. News about Pradaxa (dabigatran etexilate) and Xarelto (rivaroxaban). Danish Health and Medicines Authority (in Danish) https://sundhedsstyrelsen.dk/da/nyheder/2013/~/media/7AEFE599582A4F268E4F757B86D4799E.ashx. Accessed 19 June 2014. Gaist, 1997, The Danish prescription registries, Dan Med Bull, 44, 445 WHO Collaborating Centre for Drug Statistics methodology. Guidelines for ATC Classification and DDD Assignment 2013. WHO Collaborating Centre for Drug Statistics methodology, 2012. Lynge, 2011, The Danish National Patient Register, Scand J Public Health, 39, 30, 10.1177/1403494811401482 Pedersen, 2011, The Danish Civil Registration System, Scand J Public Health, 39, 22, 10.1177/1403494810387965 Thygesen, 2011, Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving, Scand J Public Health, 39, 12, 10.1177/1403494811399956 Poulsen, 2012, New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function, Drugs, 72, 1739, 10.2165/11635730-000000000-00000 Heidbuchel, 2013, European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non‐valvular atrial fibrillation, Europace, 15, 625, 10.1093/europace/eut083 Department of Health and Human Services, FDA. Questions: Dabigatran [Internet]. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM247244.pdf. Accessed 19 June 2014. Danish Health and Medicines Authority. Pradaxa – consider age and follow dose recommendations [Internet]. http://sundhedsstyrelsen.dk/en/news/2012/pradaxa-consider-age-and-follow-dose-recommendations. Accessed 19 June 2014. U.S. Food and Drug Administration. NDA 22‐512 Dabigatran Efficacy Review [Internet]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226704.pdf. Accessed 19 June 2014.